FDA to weigh easing limits on unproven peptides Issuu The U.S. Food and Drug Administration is moving toward allowing compounding pharmacies to produce more than a dozen injectable peptides that were banned because of potentially significant safety risks, the New York Content Analysis of US FDA Warning Letters Issued to Compounding Pharmacies Regarding Violations of Current Good Manufacturing Practices Between 2017 and 2022 Journal of Pharmaceutical Innovation Springer Nature Link FDA's Legislative Request on Rx and Compounded Drug Advertising Coalition for Healthcare Communication Compounding warning letters to 503A facilities between 2017 and 2021 Journal of the American Pharmacists Association